SPECIALIZED IN ANTIVIRAL SOLUTIONS
PROSTATE CANCER
The NTVIRIN have accomplished to cure the PROSTATE CANCER DISEASES and it shown the efficacy of 32.4% percent on CELL PROLIFERATION IN PC3 cells on experiments and found to be zero toxic in medications. In General, DRUG OF ANTI-CANCEROUS have found to be a great appeal in pharmaceutical industries, especially PROSTATE CANCER. The formulated NTVIRIN has tested against PROSTATE CANCER and it performed better activities when it compared with CURCUMIN, as a standard. The efficacy of the NTVIRIN has evaluated by MTT assay method at different concentrations. A series of NTVIRIN solution concentrations in terms of µM/ml have treated against the Influenza A H1N1.
The Anti-cancerous activities of the NTVIRIN Solutions were increased upon increasing the concentration of NTVIRIN and it has been found to be 69 % of curing the cancer cells in 72 hours. The IC50 of NTVIRIN was observed at 17.77 µM/ml.
The Anti-cancerous activities of the NTVIRIN Solutions were increased upon increasing the concentration of NTVIRIN and it has been found to be 69 % of curing the cancer cells in 72 hours. The IC50 of NTVIRIN was observed at 17.77 µM/ml.
MARKET POTENTIAL OF PROSTATE CANCER THERAPEUTICS
The global prostate cancer drugs market is witnessing remarkable expansion, with a projected value of $12.81 billion in 2022, up from $13.63 billion in 2023. This impressive growth is driven by a compound annual growth rate (CAGR) of 6.7%. The market is expected to continue its upward trajectory, reaching $17.63 billion in 2029, at a CAGR of 5.7%. The “PROSTATECANCER DRUGS GLOBAL MARKET REPORT 2023” provides valuable insights into the industry’s growth prospects and emerging trends.
The prostate cancer drugs market encompasses sales of acetate and amide based drugs It refers to drugs used for the prevention and treatment of prostate cancer, a prevalent type of cancer among men, resulting from uncontrolled cell growth in the prostate gland. Prostate cancer drugs market offers various treatment options, INCLUDING HORMONAL THERAPY, CHEMOTHERAPY, IMMUNOTHERAPY, AND TARGETED THERAPY. North America stands as the largest region in the prostate cancer drugs market in 2022, while the Middle East is predicted to be the fastest-growing region in the forecast period. The report covers market data from regions such as Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa, and includes key countries like Australia, Brazil, China, France, Germany, India, Japan, Russia, South Korea, the UK, and the USA.
PROSTATE CANCER PHARMACEUTICALS
Prostate cancer is cancer that occurs in the prostate. The prostate is a small walnut-shaped gland in males that produces the seminal fluid that nourishes and transports sperm. Prostate cancer is one of the most common types of cancer. Many prostate cancers grow slowly and are confined to the prostate gland, where they may not cause serious harm. However, while some types of prostate cancer grow slowly and may need minimal or even no treatment, other types are aggressive and can spread quickly. Prostate cancer that’s detected early — when it’s still confined to the prostate gland — has the best chance for successful treatment. Prostate cancer may cause no signs or symptoms in its early stages.
Prostate cancer that’s more advanced may cause signs and symptoms such as:
- Trouble urinating & Decreased force in the stream of urine
- Blood in the urine & in semen
- Bone pain & Losing weight without trying
- Erectile dysfunction
NTVIRIN Anti-Prostate Pharmaceuticals have Zero-cytotoxic effects to patients. And have excellent performance against the cancers.